Bristol Myers Squibb Reports Durable Sotyktu Results in PsA
PRINCETON, N.J. — September 17, 2026 Bristol Myers Squibb announced positive two-year results from the Phase 3 POETYK PsA-2...
ACR50
Advertisement
Spyre Reports SPY072 Rheumatoid Arthritis Phase 2 Results
WALTHAM, Mass. — August 25, 2026 Spyre Therapeutics, Inc. announced topline results from the rheumatoid arthritis (RA) sub-study of...
MoonLake Reports Positive Phase 3 PsA Results for Sonelokimab
ZUG, Switzerland, August 10, 2026 MoonLake Immunotherapeutics announced positive topline results from its Phase 3 IZAR-1 trial evaluating investigational...
UCB Reports BIMZELX Superior to SKYRIZI in BE BOLD PsA Study
BRUSSELS, Belgium, May 19, 2026 UCB announced new Phase 3b clinical data showing that BIMZELX® (bimekizumab) demonstrated superior efficacy...
Lilly Taltz Zepbound Combo Shows Strong Phase 3b Results
Indianapolis, USA | March 28, 2026 Phase 3b Study Demonstrates Superior Clinical Outcomes Eli Lilly and Company has announced...
Advertisement
